Cingulate Inc. , a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.
Cingulate stock last closed at $0.89, up 1.36% from the previous day, and has decreased 22.64% in one year. It has underperformed other stocks in the Biotechnology industry by 0.24 percentage points. Cingulate stock is currently +34.34% from its 52-week low of $0.66, and -55.4% from its 52-week high of $2.00.
There are currently 11.7M shares of CING outstanding. The market capitalization of CING is $10.44M. In the last 24 hours, 47,009 CING shares were traded.
How to Buy Cingulate Stock
Wondering how to invest in Cingulate stock? Here's how.
Figure out where to buy Cingulate stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you figure out where to buy Cingulate stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Deposit money your investment account: Choose your payment method and add your information.
Research Cingulate stock: The Cingulate ticker symbol is CING. Is Cingulate stock a good investment? Should you buy shares of CING? How do CING's underlying business fundamentals look? Do top analysts think Cingulate is a good buy? Why has CING's stock price moved recently? (Hint: Our stock research website can help you evaluate if CING is a good stock to buy).
Make your CING buy order: Decide if you will purchase CING shares at the current market price or use a limit order to purchase CING stock at a specific price.
Get key alerts regarding your investment in CING: Create a watchlist to get the latest news on your position in Cingulate stock.
Step 1: Figure out where to buy Cingulate stock
You will need a brokerage account in order to access the NASDAQ market and buy CING shares.
A brokerage account enables you to buy and sell a number of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
Invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to global markets: From Technology to Industrials, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal details so you are able to invest in CING stock today.
After you have selected the best place to buy Cingulate stock, it's important to evaluate their stock prior to investing, so you actually understand the risk and opportunity.
Cingulate Numbers
CING Price
$0.89
1w %
-8.98%
1y %
-22.64%
5y %
N/A
P/E
-0.61x
P/B
127.92x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$16.68M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$10.44M
Next Earnings
N/A
Next Dividend
N/A
CING Due Diligence Checks
WallStreetZen was created to help part-time investors do more accurate fundamental analysis in less time.
There are more short-term assets than long-term liabilities on the CING balance sheet.
Signs that CING is not financially healthy:
CING has a relatively high debt to equity ratio of 86.77.
CING has $1.74M in cash and short term investments. This is not sufficient to cover its annual cash burn of $15.77M.
CING has cash burn of 15774941. It does not have sufficient cash and short-term investments to cover this.
There are more short-term liabilities than short-term assets on the CING balance sheet.
Do Wall Street analysts think it's a good time to buy CING stock
Out of 1 Wall Street analysts who give ratings on CING, the consensus analyst rating on Cingulate is a Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Latest CING Analyst Forecasts
Raghuram Selvaraju, a bottom 1% analyst from HC Wainwright & Co. initiates coverage on CING with a buy rating and announces their CING price target of $5.50, on Jan 17, 2023.
No, Cingulate doesn't provide an income stream by paying out dividends.
What do other investors have to say about CING?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your CING buy order
You have two main order types:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are generally sufficient.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a given dollar amount limit, place a limit order.
Click the Open Trade button and eToro will place the order.
If you want additional info about buying stocks on eToro, click the helpful video below:
As of May 26, 2023, it costs $0.89 to buy one share of Cingulate stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.45, you can buy 0.5 shares of CING.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.